What to Expect in 2026?
As drug discovery pipelines face increasing pressure to deliver confident decisions earlier, structure-based drug design is becoming a central driver of modern R&D strategy. Biopharma organizations are increasingly combining high-resolution structural biology with AI-enabled modelling and computational design to unlock complex targets, prioritize compounds faster and reduce risk across discovery programs.
However, as predictive technologies advance, their impact ultimately depends on high-quality experimental validation and robust structural data. The ability to integrate AI, structural biology and wet-lab experimentation is now critical for translating structural insight into meaningful discovery decisions.
The 3rd Structure-Based Drug Design Summit brings together structural biologists, medicinal chemists, computational scientists and discovery leaders to explore how these technologies are being applied in practice. Through real-world case studies, interactive discussions and collaborative networking, the meeting will highlight how leading organizations are leveraging experimental techniques and integrating structural biology and AI-driven modelling to accelerate early drug discovery and tackle increasingly complex targets.
Designed with biopharma, for biopharma, the summit focuses on practical implementation, addressing shared technical challenges such as construct optimization, conformational heterogeneity and data integration while exploring strategies to strengthen confidence in structure-enabled discovery decisions.
Unmissable Event Highlights
Move Beyond Structure Generation to Structure-Driven Decision Making
Discover how leading organizations are integrating structural biology with medicinal chemistry, computational modelling and AI to accelerate discovery programmes, with insights from Insitro , Harvard Medical School, Sanofi and Monte Rosa Therapeutics.
Explore How Structural Biology is Unlocking Complex Targets
Hear real-world case studies tackling dynamic and challenging systems including GPCRs, ion channels, induced-proximity complexes and antiviral targets, with experts from Tango Therapeutics, GSK, Confo Therapeutics, and Novartis.
Understand the Realities of Modern Cryo-EM Pipelines
Join an interactive discussion exploring the practical constraints shaping cryo-EM adoption—from data processing and conformational heterogeneity to access and timelines—with experts from AbbVie, Revolution Medicines, Genesis Therapeutics and Vividion Therapeutics.
Discover New Opportunities to Expand Druggable Spac
Learn how structural biology is revealing cryptic pockets, resolving multi-protein complexes and enabling fragment-based discovery strategies, with insights from Pfizer, MOMA Therapeutics and Gilead Sciences.
Explore the Future of Structural Data Collaboration for AI
Understand how federated learning and shared structural datasets could unlock the next generation of predictive models while protecting proprietary data, with insights from the Oxford Centre for Medicines Discovery.
Benchmark AI & Experimental Workflows in Interactive Discussions
Compare real-world modelling strategies, discuss bottlenecks in structural data generation and share approaches for aligning computational prediction with experimental validation in a collaborative exchange led by Monte Rosa Therapeutics.
Explore the Full Event Guide
- 23 Expert Speakers From Pfizer, AstraZeneca, Gilead Sciences, Takeda, AbbVie & More
- 3 Hands-on Workshops Covering Cryo-EM Workflows, Structural Strategy & Protein Design
- 12+ Case Studies & Technical Talks Exploring AI-enabled SBDD, Cryo-EM & Complex Targets
- 8+ Hours of Dedicated Networking & Collaborative Discussions with Discovery Leaders
- Real-World Industry Insights Across GPCR’s, Membrane Proteins, Induced Proximity & Biologic
Attending Companies Include
Explore the Agenda
Preview expert-led case studies on AI-enabled structure-based drug design, cryo-EM breakthroughs and complex target biology, alongside interactive discussions and hands-on workshops across three content-rich days.
Partner With Us
Position your organization as the go-to solution provider by showcasing your technologies, services and expertise to structural biology and drug discovery leaders shaping the next generation of discovery workflows.
Join Biopharma Experts
Connect with structural biologists, medicinal chemists, computational scientists and discovery leaders through collaborative discussions, roundtables and dedicated networking sessions to elevate structural insights and strengthen discovery decisions.